CA2750242C - Drug delivery through hydrogel plugs - Google Patents
Drug delivery through hydrogel plugs Download PDFInfo
- Publication number
- CA2750242C CA2750242C CA2750242A CA2750242A CA2750242C CA 2750242 C CA2750242 C CA 2750242C CA 2750242 A CA2750242 A CA 2750242A CA 2750242 A CA2750242 A CA 2750242A CA 2750242 C CA2750242 C CA 2750242C
- Authority
- CA
- Canada
- Prior art keywords
- hydrogel
- drug
- prosthesis
- release
- microspheres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 389
- 238000012377 drug delivery Methods 0.000 title description 14
- 239000003814 drug Substances 0.000 claims abstract description 298
- 229940079593 drug Drugs 0.000 claims abstract description 248
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 91
- 241000083513 Punctum Species 0.000 claims abstract description 41
- 238000000338 in vitro Methods 0.000 claims abstract description 23
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 7
- 230000000903 blocking effect Effects 0.000 claims abstract description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 5
- 239000002243 precursor Substances 0.000 claims description 148
- 239000004005 microsphere Substances 0.000 claims description 119
- 239000003795 chemical substances by application Substances 0.000 claims description 92
- 229920000642 polymer Polymers 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 86
- 125000000524 functional group Chemical group 0.000 claims description 83
- 239000000243 solution Substances 0.000 claims description 70
- 239000000463 material Substances 0.000 claims description 69
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 47
- 229960003702 moxifloxacin Drugs 0.000 claims description 45
- 229920001223 polyethylene glycol Polymers 0.000 claims description 42
- 239000002202 Polyethylene glycol Substances 0.000 claims description 40
- 230000008569 process Effects 0.000 claims description 37
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 36
- 229960001160 latanoprost Drugs 0.000 claims description 35
- 238000011068 loading method Methods 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 239000007864 aqueous solution Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 239000012530 fluid Substances 0.000 claims description 19
- 238000012800 visualization Methods 0.000 claims description 18
- 238000001727 in vivo Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 230000000977 initiatory effect Effects 0.000 claims description 15
- 150000003254 radicals Chemical class 0.000 claims description 14
- 238000005538 encapsulation Methods 0.000 claims description 13
- 230000001186 cumulative effect Effects 0.000 claims description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 11
- 206010030043 Ocular hypertension Diseases 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 229920001059 synthetic polymer Polymers 0.000 claims description 11
- 108010036949 Cyclosporine Proteins 0.000 claims description 10
- 238000009826 distribution Methods 0.000 claims description 10
- 208000010412 Glaucoma Diseases 0.000 claims description 9
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 9
- 230000004410 intraocular pressure Effects 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 8
- 230000004406 elevated intraocular pressure Effects 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 229960001265 ciclosporin Drugs 0.000 claims description 7
- 229930182912 cyclosporin Natural products 0.000 claims description 7
- 150000003573 thiols Chemical class 0.000 claims description 6
- 229920003169 water-soluble polymer Polymers 0.000 claims description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 239000012216 imaging agent Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 5
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 230000007073 chemical hydrolysis Effects 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 229960002368 travoprost Drugs 0.000 claims description 4
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 210000001508 eye Anatomy 0.000 description 53
- -1 droplet Substances 0.000 description 46
- 239000012071 phase Substances 0.000 description 44
- 238000004132 cross linking Methods 0.000 description 43
- 239000002904 solvent Substances 0.000 description 42
- 230000008961 swelling Effects 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- 230000002209 hydrophobic effect Effects 0.000 description 32
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 32
- 239000000499 gel Substances 0.000 description 30
- 239000011859 microparticle Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000725 suspension Substances 0.000 description 27
- 238000011065 in-situ storage Methods 0.000 description 23
- 239000003960 organic solvent Substances 0.000 description 23
- 239000011159 matrix material Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 18
- 230000000269 nucleophilic effect Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000015556 catabolic process Effects 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- 229920000747 poly(lactic acid) Polymers 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000006116 polymerization reaction Methods 0.000 description 15
- 238000009472 formulation Methods 0.000 description 13
- 239000003999 initiator Substances 0.000 description 13
- 239000000178 monomer Substances 0.000 description 13
- 239000004626 polylactic acid Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 208000002205 allergic conjunctivitis Diseases 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 238000010348 incorporation Methods 0.000 description 12
- 239000008215 water for injection Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000000935 solvent evaporation Methods 0.000 description 11
- 239000004971 Cross linker Substances 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 229920000260 silastic Polymers 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000013270 controlled release Methods 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 239000000412 dendrimer Substances 0.000 description 9
- 229920000736 dendritic polymer Polymers 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 150000003431 steroids Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 208000024998 atopic conjunctivitis Diseases 0.000 description 8
- 229920001002 functional polymer Polymers 0.000 description 8
- 229920000728 polyester Polymers 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 210000000795 conjunctiva Anatomy 0.000 description 7
- 239000006196 drop Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 150000003141 primary amines Chemical class 0.000 description 7
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 6
- NWAGXLBTAPTCPR-UHFFFAOYSA-N 5-(2,5-dioxopyrrolidin-1-yl)oxy-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)ON1C(=O)CCC1=O NWAGXLBTAPTCPR-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229920002988 biodegradable polymer Polymers 0.000 description 6
- 239000004621 biodegradable polymer Substances 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 239000000693 micelle Substances 0.000 description 6
- 239000012038 nucleophile Substances 0.000 description 6
- 229940068984 polyvinyl alcohol Drugs 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000000807 solvent casting Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 5
- 241000282465 Canis Species 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 5
- 229920006037 cross link polymer Polymers 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960003923 gatifloxacin Drugs 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 229960002800 prednisolone acetate Drugs 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000012713 reactive precursor Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 229920002732 Polyanhydride Polymers 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 201000011190 diabetic macular edema Diseases 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 229940065514 poly(lactide) Drugs 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 4
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 3
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 3
- 238000012644 addition polymerization Methods 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000011243 crosslinked material Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 206010014801 endophthalmitis Diseases 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001308 poly(aminoacid) Polymers 0.000 description 3
- 239000012704 polymeric precursor Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 229940127293 prostanoid Drugs 0.000 description 3
- 150000003814 prostanoids Chemical class 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000012431 wafers Nutrition 0.000 description 3
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- JWUFSYXQWPXFIL-UHFFFAOYSA-N 6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexanoic acid Chemical compound OC(=O)CCCCC(=O)ON1C(=O)CCC1=O JWUFSYXQWPXFIL-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010058202 Cystoid macular oedema Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 238000005354 coacervation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 201000010206 cystoid macular edema Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 2
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229910001448 ferrous ion Inorganic materials 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000009474 immediate action Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 2
- 229940101459 loteprednol etabonate ophthalmic suspension Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 2
- 235000010298 natamycin Nutrition 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 238000007344 nucleophilic reaction Methods 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 239000000622 polydioxanone Substances 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 229940034215 vigamox Drugs 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- WTFAGPBUAGFMQX-UHFFFAOYSA-N 1-[2-[2-(2-aminopropoxy)propoxy]propoxy]propan-2-amine Chemical compound CC(N)COCC(C)OCC(C)OCC(C)N WTFAGPBUAGFMQX-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical group C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 1
- BLSAPDZWVFWUTL-UHFFFAOYSA-N 2,5-dioxopyrrolidine-3-sulfonic acid Chemical group OS(=O)(=O)C1CC(=O)NC1=O BLSAPDZWVFWUTL-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 description 1
- YVYGHRNLPUMVBU-UHFFFAOYSA-N 2-Hydroxy-2-ethylsuccinic acid Chemical compound CCC(O)(C(O)=O)CC(O)=O YVYGHRNLPUMVBU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- MXRGSJAOLKBZLU-UHFFFAOYSA-N 3-ethenylazepan-2-one Chemical compound C=CC1CCCCNC1=O MXRGSJAOLKBZLU-UHFFFAOYSA-N 0.000 description 1
- VFXXTYGQYWRHJP-UHFFFAOYSA-N 4,4'-azobis(4-cyanopentanoic acid) Chemical group OC(=O)CCC(C)(C#N)N=NC(C)(CCC(O)=O)C#N VFXXTYGQYWRHJP-UHFFFAOYSA-N 0.000 description 1
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000016134 Conjunctival disease Diseases 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- KSQCNBKUWZNXBK-UHFFFAOYSA-N N'-(2,5-dioxopyrrolidin-1-yl)pentanediamide Chemical compound NC(=O)CCCC(=O)NN1C(=O)CCC1=O KSQCNBKUWZNXBK-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 150000001255 actinides Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940060610 alrex Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- 229940059222 betimol Drugs 0.000 description 1
- 229940072329 betoptic Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229940006072 bimatoprost ophthalmic solution Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000002362 bornane-2,3-dione group Chemical group 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 238000007156 chain growth polymerization reaction Methods 0.000 description 1
- 239000012986 chain transfer agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940088515 ciloxan Drugs 0.000 description 1
- MPMSMUBQXQALQI-UHFFFAOYSA-N cobalt phthalocyanine Chemical compound [Co+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 MPMSMUBQXQALQI-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003500 cycloplegic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940090570 dipivefrin hydrochloride Drugs 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- UKZQEOHHLOYJLY-UHFFFAOYSA-M ethyl eosin Chemical group [K+].CCOC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 UKZQEOHHLOYJLY-UHFFFAOYSA-M 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229940058429 fluorometholone ophthalmic suspension Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 229940110775 latanoprost ophthalmic solution Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000010550 living polymerization reaction Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229940080267 lotemax Drugs 0.000 description 1
- 229940112534 lumigan Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229940058192 moxifloxacin ophthalmic solution Drugs 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940064801 natacyn Drugs 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940012664 nevanac Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229940061037 optivar Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000012643 polycondensation polymerization Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229940090942 povidone-iodine ophthalmic solution Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 108010061115 tetralysine Proteins 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- YRHRIQCWCFGUEQ-UHFFFAOYSA-N thioxanthen-9-one Chemical group C1=CC=C2C(=O)C3=CC=CC=C3SC2=C1 YRHRIQCWCFGUEQ-UHFFFAOYSA-N 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940113006 travatan Drugs 0.000 description 1
- 229940089406 travoprost ophthalmic solution Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GOCYOWTYSKXMTR-UHFFFAOYSA-N trisodium borate dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]B([O-])[O-] GOCYOWTYSKXMTR-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229920003170 water-soluble synthetic polymer Polymers 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12159—Solid plugs; being solid before insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/1219—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00772—Apparatus for restoration of tear ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15208109P | 2009-02-12 | 2009-02-12 | |
| US61/152,081 | 2009-02-12 | ||
| PCT/US2010/024029 WO2010093873A2 (en) | 2009-02-12 | 2010-02-12 | Drug delivery through hydrogel plugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2750242A1 CA2750242A1 (en) | 2010-08-19 |
| CA2750242C true CA2750242C (en) | 2018-05-22 |
Family
ID=42560121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2750242A Active CA2750242C (en) | 2009-02-12 | 2010-02-12 | Drug delivery through hydrogel plugs |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8409606B2 (enExample) |
| EP (1) | EP2396070B1 (enExample) |
| JP (1) | JP5890182B2 (enExample) |
| CN (1) | CN102395401B (enExample) |
| AU (1) | AU2010213612B2 (enExample) |
| CA (1) | CA2750242C (enExample) |
| WO (1) | WO2010093873A2 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| EP2276439A4 (en) | 2008-05-12 | 2013-11-27 | Univ Utah Res Found | DEVICE AND CORRESPONDING METHODS FOR INTRAOCULAR MEDICAMENT ADMINISTRATION |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| JP5695035B2 (ja) | 2009-06-03 | 2015-04-01 | フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． | 前眼部薬物供給 |
| CA2779104C (en) * | 2009-10-30 | 2018-07-17 | Aton Pharma, Inc. | Ocular drug delivery devices |
| US10189773B2 (en) | 2010-05-07 | 2019-01-29 | Medicus Biosciences, Llc | In-vivo gelling pharmaceutical pre-formulation |
| SG187770A1 (en) | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
| US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
| EP3821820B1 (en) | 2011-01-19 | 2024-11-20 | Access Closure, Inc. | Apparatus and methods of manufacturing a sealing for a vascular puncture |
| US9820728B2 (en) | 2011-01-19 | 2017-11-21 | Access Closure, Inc. | Apparatus and methods for sealing a vascular puncture |
| US20160144038A1 (en) * | 2014-11-20 | 2016-05-26 | Broda International, LLC | Water-soluble supramolecular complexes |
| WO2012149278A1 (en) * | 2011-04-29 | 2012-11-01 | Allergan, Inc. | Sustained release latanoprost implant |
| JP6223963B2 (ja) | 2011-05-18 | 2017-11-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 網膜疾患を処置するための組成物および方法 |
| WO2013006661A2 (en) | 2011-07-06 | 2013-01-10 | President And Fellows Of Harvard College | Multiple emulsions and techniques for the formation of multiple emulsions |
| US11083821B2 (en) | 2011-08-10 | 2021-08-10 | C.P. Medical Corporation | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
| US10111985B2 (en) | 2011-08-10 | 2018-10-30 | Medicus Biosciences, Llc | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
| ES2912370T3 (es) | 2011-09-14 | 2022-05-25 | Forsight Vision5 Inc | Aparato para inserción ocular |
| US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
| EP2578190A1 (en) * | 2011-10-07 | 2013-04-10 | Sanofi-Aventis Deutschland GmbH | Intraocular injection device |
| EP3613413A1 (en) * | 2011-12-05 | 2020-02-26 | Incept, LLC | Medical organogel processes and compositions |
| ITVR20120051A1 (it) * | 2012-03-20 | 2013-09-21 | Bbs Srl | Composizione colorata per uso in metodi chirurgici oftalmici |
| CN104271191B (zh) * | 2012-05-08 | 2017-06-06 | 昊朗科技（佛山）有限公司 | 基于水凝胶的传送和传感器 |
| EP2846847B1 (en) | 2012-05-11 | 2020-03-25 | C.P. Medical Corporation | Biocompatible hydrogel treatments for retinal detachment |
| CA2881010A1 (en) * | 2012-08-06 | 2014-02-13 | Baylor College Of Medicine | Therapeutics dispensing device and methods of making same |
| CN104884006B (zh) | 2012-10-26 | 2017-12-15 | 弗赛特影像5股份有限公司 | 用于持续释放药物到眼睛的眼科系统 |
| CZ2012922A3 (cs) * | 2012-12-19 | 2014-08-13 | Lucie Palasová | Prostředek k odstraňování nežádoucích substancí a předmětů, jakými jsou odpadní produkty metabolizmu, nečistoty, prach a zbytky kosmetiky, z oblasti oka a způsob jeho výroby |
| CN105142710A (zh) | 2013-01-15 | 2015-12-09 | 科罗拉多州立大学董事会,公司实体 | 泪腺系统给药装置 |
| WO2014138085A1 (en) | 2013-03-05 | 2014-09-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery |
| CN105188666A (zh) * | 2013-04-01 | 2015-12-23 | 阿勒根公司 | 用于持续的眼内释放的微球药物递送系统 |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| CZ306792B6 (cs) * | 2014-05-21 | 2017-07-12 | Lucie Palasová | Prostředek pro manipulaci s kontaktní čočkou v oblasti oka a způsoby jeho výroby |
| KR102703232B1 (ko) | 2014-05-29 | 2024-09-06 | 액세스클로저, 아이엔씨. | 키토산 및 폴리에틸렌 글리콜 공중합체 및 이를 사용하여 혈관 천공을 밀봉하기 위한 방법 및 디바이스 |
| CN105266952A (zh) * | 2014-07-09 | 2016-01-27 | 首都医科大学附属北京同仁医院 | 一种抗青光眼手术中所用防术后结膜粘连的器材 |
| ES2900025T3 (es) | 2014-09-06 | 2022-03-15 | Integral Biosystems Llc | Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo |
| WO2016085746A1 (en) * | 2014-11-24 | 2016-06-02 | President And Fellows Of Harvard College | Multiple emulsions comprising rigidified portions |
| WO2016100355A1 (en) * | 2014-12-15 | 2016-06-23 | The Regents Of The University Of Colorado, A Body Corporate | Biocompatible hydrogels, systems including the hydrogels, and methods of using and forming same |
| EP3233058A1 (en) | 2014-12-15 | 2017-10-25 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
| WO2016168141A1 (en) | 2015-04-13 | 2016-10-20 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| CN107921237A (zh) | 2015-04-27 | 2018-04-17 | 反射医学公司 | 交感神经心肺神经调节系统和方法 |
| EP4279064A3 (en) * | 2015-05-12 | 2024-02-28 | Incept, LLC | Drug delivery from hydrogels |
| WO2017015591A1 (en) * | 2015-07-22 | 2017-01-26 | Incept, Llc | Coated punctal plug |
| WO2017053686A1 (en) * | 2015-09-24 | 2017-03-30 | Massachusetts Eye And Ear Infirmary | Drug delivery system and methods of use |
| BR112018004894B1 (pt) | 2015-09-29 | 2021-03-16 | Kimberly-Clark Worldwide, Inc | substrato e método para sua fabricação |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| CN108367079B (zh) | 2015-11-12 | 2022-11-22 | 灰色视觉公司 | 用于治疗的聚集性微粒 |
| EP3380040B1 (en) | 2015-11-23 | 2023-04-19 | The Regents of The University of Colorado, A Body Corporate | Lacrimal system for drug delivery |
| WO2017091749A1 (en) * | 2015-11-25 | 2017-06-01 | Incept, Llc | Shape changing drug delivery devices and methods |
| WO2017139487A1 (en) | 2016-02-09 | 2017-08-17 | Northwind Medical, Inc. | Methods, agents, and devices for local neuromodulation of autonomic nerves |
| US11207211B2 (en) | 2016-05-20 | 2021-12-28 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal drug delivery device |
| US11497399B2 (en) | 2016-05-31 | 2022-11-15 | Qura, Inc. | Implantable intraocular pressure sensors and methods of use |
| US11395853B2 (en) | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
| CN110035754A (zh) | 2016-06-29 | 2019-07-19 | 图拉维治疗股份有限公司 | 通过自主神经系统的局部神经调节治疗败血症及相关炎性病况 |
| WO2018011040A1 (en) * | 2016-07-13 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Plga microparticles loaded with a fluoroquinolone for the treatment of respiratory diseases |
| JP7430529B2 (ja) * | 2016-09-23 | 2024-02-13 | インセプト・リミテッド・ライアビリティ・カンパニー | 前房内薬物送達デポ |
| GB2575532B (en) * | 2016-10-25 | 2022-07-13 | Kimberly Clark Co | Porous, wet-triggered shrinkable materials |
| EP3621654A4 (en) | 2017-05-10 | 2021-02-17 | Graybug Vision, Inc. | PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY |
| TWI860974B (zh) | 2017-06-05 | 2024-11-11 | 加州大學董事會 | 用來治療視網膜疾病之製劑的製造方法 |
| CN107789093B (zh) * | 2017-10-30 | 2020-05-05 | 广州新诚生物科技有限公司 | 自膨胀固定的人工鼻泪管 |
| WO2019164940A1 (en) * | 2018-02-20 | 2019-08-29 | Qura, Inc. | Coating for implantable devices |
| MX2020008760A (es) | 2018-03-22 | 2020-09-28 | Kimberly Clark Co | Productos con materiales que se encogen en una dimension y se expanden en otra dimension. |
| US20210315587A1 (en) | 2018-07-02 | 2021-10-14 | Tulavi Therapeutics, Inc. | Methods and devices for in situ formed nerve cap with rapid release |
| AU2019299519B2 (en) | 2018-07-02 | 2025-03-06 | Incept Llc | Methods and devices for in situ formed nerve cap |
| CN109077993B (zh) * | 2018-08-31 | 2021-03-16 | 北京诺康达医药科技股份有限公司 | 一种泪小管缓释水凝胶植入剂及其制备方法 |
| CN109350355B (zh) * | 2018-11-30 | 2023-09-12 | 西安市第四医院 | 一种smile手术来源角膜基质透镜泪道栓及其制备方法 |
| JP2022530142A (ja) * | 2019-04-25 | 2022-06-27 | オキュラ セラピューティクス，インコーポレイテッド | 麻酔薬を送達するための小管内ヒドロゲル挿入物 |
| CN114096339B (zh) * | 2019-05-02 | 2024-04-12 | 特清公司 | 从滴眼剂中去除防腐剂 |
| EP4009857B1 (en) * | 2019-08-06 | 2025-08-20 | DOSE Medical Corporation | Bioerodible cross-linked hydrogel implants and related methods of use |
| CA3166738A1 (en) | 2020-02-06 | 2021-08-12 | Charles D. Blizzard | Travoprost compositions and methods for treating ocular diseases |
| FI3884929T3 (fi) | 2020-03-25 | 2023-08-07 | Ocular Therapeutix Inc | Tyrosiinikinaasi-inhibiittoria sisältävä silmäimplantti |
| CA3177005A1 (en) * | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| CN111773178B (zh) * | 2020-06-08 | 2022-11-25 | 北京诺康达医药科技股份有限公司 | 水凝胶泪道栓及其制备方法 |
| KR20230041708A (ko) * | 2020-07-16 | 2023-03-24 | 오큘라 테라퓨틱스, 인코포레이티드 | 글루코코르티코이드를 함유하는 안구 삽입물 |
| EP4216929A1 (en) | 2020-09-24 | 2023-08-02 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent |
| EP4344745A3 (en) * | 2020-09-24 | 2024-10-09 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine |
| US20230414495A1 (en) * | 2020-11-09 | 2023-12-28 | Eximore Ltd. | Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof |
| US12343454B2 (en) | 2020-11-12 | 2025-07-01 | Pramand LLC | Hydrogels formed in situ and composition design for intrauterine use |
| JP2024508811A (ja) * | 2021-02-24 | 2024-02-28 | オキュラ セラピューティクス，インコーポレイテッド | 小管内デポーインサータ装置 |
| FR3120563B1 (fr) | 2021-03-11 | 2023-03-17 | Hexcel Reinforcements | Nouveaux matériaux de renfort à base de fils torsadés S et Z, adaptés à la constitution de pièces composites, procédés et utilisation |
| US20250134908A1 (en) | 2021-08-06 | 2025-05-01 | Calosyn Pharma Inc. | Therapeutics and method for treating osteoarthritis |
| US20250009644A1 (en) * | 2021-12-02 | 2025-01-09 | University Of Connecticut | Long-acting injectable in situ forming biodegradable implants comprising non-steroidal anti-inflammatory drugs |
| CN120641081A (zh) * | 2023-02-17 | 2025-09-12 | 视尔普斯眼科公司 | 用于持续药物递送的可生物降解微粒、其制备方法及用途 |
| CN120897764A (zh) | 2023-04-11 | 2025-11-04 | 视尔普斯眼科公司 | 包含阿西替尼多晶型物iv的眼部植入物 |
| CN120459010A (zh) * | 2024-04-29 | 2025-08-12 | 浙江瑞瞳生物科技有限公司 | 泪小管插入剂的制备方法和泪小管插入剂 |
Family Cites Families (382)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1280808A (en) | 1918-02-06 | 1918-10-08 | Hofmann Morgan Rubber Company | Pneumatic tire. |
| NL128865C (enExample) | 1961-09-05 | |||
| US3520949A (en) | 1966-07-26 | 1970-07-21 | Nat Patent Dev Corp | Hydrophilic polymers,articles and methods of making same |
| US3423489A (en) | 1966-11-01 | 1969-01-21 | Minnesota Mining & Mfg | Encapsulation process |
| US3626940A (en) | 1969-05-02 | 1971-12-14 | Alza Corp | Ocular insert |
| US3618604A (en) | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
| US3640741A (en) | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
| US3779942A (en) | 1970-12-04 | 1973-12-18 | Minnesota Mining & Mfg | Capsules and process for forming capsules |
| US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
| US3993071A (en) | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
| US3981303A (en) | 1971-09-09 | 1976-09-21 | Alza Corporation | Bioerodible ocular device |
| US3962414A (en) | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3975350A (en) | 1972-08-02 | 1976-08-17 | Princeton Polymer Laboratories, Incorporated | Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles |
| US3991766A (en) | 1973-05-31 | 1976-11-16 | American Cyanamid Company | Controlled release of medicaments using polymers from glycolic acid |
| US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| DE2437629C3 (de) | 1974-08-05 | 1978-09-21 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von unlöslichen in Wasser nur wenig quellbaren Polymerisaten von N-Vinyllactamen |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US3949750A (en) | 1974-10-07 | 1976-04-13 | Freeman Jerre M | Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same |
| US3949073A (en) | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| IL47468A (en) | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
| US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4195129A (en) | 1975-11-26 | 1980-03-25 | Kansai Paint Co., Ltd. | Method for immobilizing enzymes and microbial cells |
| US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
| US4268495A (en) | 1979-01-08 | 1981-05-19 | Ethicon, Inc. | Injectable embolization and occlusion solution |
| AT359652B (de) | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| US4247406A (en) | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
| US4311146A (en) | 1980-05-08 | 1982-01-19 | Sorenson Research Co., Inc. | Detachable balloon catheter apparatus and method |
| DE3265697D1 (en) | 1981-02-05 | 1985-10-03 | Nippon Oil Co Ltd | Process for preparing a hydrogel |
| US4532134A (en) | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
| JPS585320A (ja) | 1981-07-01 | 1983-01-12 | Toray Ind Inc | グラフト共重合体 |
| DE3128923A1 (de) | 1981-07-22 | 1983-02-10 | Beiersdorf Ag, 2000 Hamburg | Pulvermischung fuer chirurgische zwecke |
| US4734097A (en) | 1981-09-25 | 1988-03-29 | Nippon Oil Company, Ltd. | Medical material of polyvinyl alcohol and process of making |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| JPS5930881A (ja) | 1982-08-13 | 1984-02-18 | Nippon Oil Co Ltd | 保冷用ゲルの製造法 |
| US4568737A (en) | 1983-01-07 | 1986-02-04 | The Dow Chemical Company | Dense star polymers and dendrimers |
| US4507466A (en) | 1983-01-07 | 1985-03-26 | The Dow Chemical Corporation | Dense star polymers having core, core branches, terminal groups |
| US4631188A (en) | 1983-08-31 | 1986-12-23 | S.K.Y. Polymers, Ltd. (Kingston Technologies) | Injectable physiologically-acceptable polymeric composition |
| US4693887A (en) | 1983-09-15 | 1987-09-15 | The Kendall Company | Microphase separated hydrogels for controlled release of bioactive materials |
| US4828857A (en) | 1984-10-05 | 1989-05-09 | Warner-Lambert Company | Novel sweetener delivery systems |
| US4597970A (en) | 1984-10-05 | 1986-07-01 | Warner-Lambert Company | Chewing gum compositions containing novel sweetener delivery systems and method of preparation |
| US4839345A (en) | 1985-03-09 | 1989-06-13 | Nippon Oil And Fats Co., Ltd. | Hydrated adhesive gel and method for preparing the same |
| US4740534A (en) | 1985-08-30 | 1988-04-26 | Sanyo Chemical Industries, Ltd. | Surgical adhesive |
| US4717378A (en) | 1986-03-31 | 1988-01-05 | Medtronic, Inc. | Methods for detecting dehydration of a biomedical hydrogel |
| US5510254A (en) | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
| US4760131A (en) | 1986-04-23 | 1988-07-26 | Collagen Corporation | Wound-healing composition |
| US4741872A (en) | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
| US5160745A (en) | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
| US4646730A (en) | 1986-05-23 | 1987-03-03 | Johnson & Johnson Products, Inc. | Color stabilized hydrogel dressing and process |
| US4803075A (en) | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
| US4837381A (en) | 1986-08-11 | 1989-06-06 | American Cyanamid Company | Compositions for parenteral administration and their use |
| US4979959A (en) | 1986-10-17 | 1990-12-25 | Bio-Metric Systems, Inc. | Biocompatible coating for solid surfaces |
| US4952581A (en) | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
| IL82834A (en) | 1987-06-09 | 1990-11-05 | Yissum Res Dev Co | Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom |
| US4804691A (en) | 1987-08-28 | 1989-02-14 | Richards Medical Company | Method for making a biodegradable adhesive for soft living tissue |
| US5024742A (en) | 1988-02-24 | 1991-06-18 | Cedars-Sinai Medical Center | Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers |
| US5281662A (en) | 1988-08-03 | 1994-01-25 | New England Deaconess Hospital Corporation | Anthraquinone dye treated materials |
| US5213580A (en) | 1988-08-24 | 1993-05-25 | Endoluminal Therapeutics, Inc. | Biodegradable polymeric endoluminal sealing process |
| US5843156A (en) | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US5041292A (en) | 1988-08-31 | 1991-08-20 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4911926A (en) | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
| US5126141A (en) | 1988-11-16 | 1992-06-30 | Mediventures Incorporated | Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides |
| US5681576A (en) | 1988-11-16 | 1997-10-28 | Mdv Technologies, Inc. | Method and composition for post surgical adhesion reduction |
| US5527856A (en) | 1988-11-21 | 1996-06-18 | Collagen Corporation | Method of preparing crosslinked biomaterial compositions for use in tissue augmentation |
| US5936035A (en) | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
| US5800541A (en) | 1988-11-21 | 1998-09-01 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
| US5565519A (en) | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
| US5475052A (en) | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
| US5614587A (en) | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
| US5306500A (en) | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
| US5643464A (en) | 1988-11-21 | 1997-07-01 | Collagen Corporation | Process for preparing a sterile, dry crosslinking agent |
| US5550187A (en) | 1988-11-21 | 1996-08-27 | Collagen Corporation | Method of preparing crosslinked biomaterial compositions for use in tissue augmentation |
| US5304595A (en) | 1988-11-21 | 1994-04-19 | Collagen Corporation | Collagen-polymer conjugates |
| US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| IL90193A (en) | 1989-05-04 | 1993-02-21 | Biomedical Polymers Int | Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
| US5152782A (en) | 1989-05-26 | 1992-10-06 | Impra, Inc. | Non-porous coated ptfe graft |
| US5226877A (en) | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
| US5171148A (en) | 1989-06-30 | 1992-12-15 | Ethicon, Inc. | Dental inserts for treatment of periodontal disease |
| US5776493A (en) | 1989-07-14 | 1998-07-07 | Alza Corporation | Oral osmotic device for delivery of nystatin with hydrogel driving member |
| US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| US5104909A (en) | 1989-09-21 | 1992-04-14 | W. R. Grace & Co.-Conn. | Water-absorbent, high capacity polyurethane foams |
| DK469989D0 (da) | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| US5041929A (en) | 1989-09-29 | 1991-08-20 | Storage Technology Corporation | Autoloader for magnetic tape cartridges |
| US5093319A (en) | 1989-10-31 | 1992-03-03 | Pfizer Hospital Products Group, Inc. | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions |
| US4994277A (en) | 1989-10-31 | 1991-02-19 | Pfizer Hospital Products Group, Inc. | Use of xanthan gum for preventing adhesions |
| US5468811A (en) | 1989-11-02 | 1995-11-21 | National Patent Development Corporation | Hydrophilic composite polymer articles formed from a settable paste comprising a mixture of hydrophilic polymer and unsaturated monomer |
| US5198220A (en) | 1989-11-17 | 1993-03-30 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
| US5185152A (en) | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
| US5227372A (en) | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
| US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| US6517824B1 (en) | 1990-05-14 | 2003-02-11 | University Of Medicine & Denistry Of New Jersey | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
| US5292362A (en) | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
| US5631329A (en) | 1990-08-27 | 1997-05-20 | Dendritech, Inc. | Process for producing hyper-comb-branched polymers |
| US5266325A (en) | 1990-09-28 | 1993-11-30 | Hydro Med Science Division Of National Patent Development Corp. | Preparation of homogeneous hydrogel copolymers |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5380536A (en) | 1990-10-15 | 1995-01-10 | The Board Of Regents, The University Of Texas System | Biocompatible microcapsules |
| US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5232984A (en) | 1990-10-15 | 1993-08-03 | The Board Of The Regents The University Of Texas | Biocompatible microcapsules |
| US5167624A (en) | 1990-11-09 | 1992-12-01 | Catheter Research, Inc. | Embolus delivery system and method |
| US5143662A (en) | 1991-02-12 | 1992-09-01 | United States Surgical Corporation | Process for preparing particles of bioabsorbable polymer |
| AU654857B2 (en) | 1991-03-29 | 1994-11-24 | Collagen Corporation | Device and method for treating facial lines |
| US5296518A (en) | 1991-05-24 | 1994-03-22 | Hampshire Chemical Corp. | Hydrophilic polyurethaneurea foams containing no toxic leachable additives and method to produce such foams |
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
| IL102941A0 (en) | 1991-08-27 | 1993-01-31 | Thomas R Johnson | Injection syringe |
| US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
| US5283063A (en) | 1992-01-31 | 1994-02-01 | Eagle Vision | Punctum plug method and apparatus |
| JP2855307B2 (ja) | 1992-02-05 | 1999-02-10 | 生化学工業株式会社 | 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法 |
| US5213760A (en) | 1992-02-19 | 1993-05-25 | Allergan, Inc. | Overworn lens signaling methodology |
| US5334137A (en) | 1992-02-21 | 1994-08-02 | Eagle Vision, Inc. | Lacrimal fluid control device |
| BR9306038A (pt) | 1992-02-28 | 1998-01-13 | Univ Texas | Hidrogéis biodegradáveis fotopolimerizáveis como materiais de contato de tecidos e condutores de liberação controlada |
| US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5296228A (en) | 1992-03-13 | 1994-03-22 | Allergan, Inc. | Compositions for controlled delivery of pharmaceutical compounds |
| US5266326A (en) | 1992-06-30 | 1993-11-30 | Pfizer Hospital Products Group, Inc. | In situ modification of alginate |
| AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
| US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
| IL106660A (en) | 1992-08-13 | 1997-04-15 | Adcock Ingram Ltd | Hydrogel composition comprising polyvinyl alcohol polymer and its production |
| AU683022B2 (en) | 1992-09-10 | 1997-10-30 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| US5844023A (en) | 1992-11-06 | 1998-12-01 | Bio-Tec Biologische Naturverpackungen Gmbh | Biologically degradable polymer mixture |
| US5286257A (en) | 1992-11-18 | 1994-02-15 | Ultradent Products, Inc. | Syringe apparatus with detachable mixing and delivery tip |
| AU675252B2 (en) | 1992-12-18 | 1997-01-30 | Tremco, Inc. | Fast-curing, high strength, two-part sealants using acetoacetate-amine cure chemistry |
| JP3390477B2 (ja) | 1993-01-25 | 2003-03-24 | 生化学工業株式会社 | 薬剤組成物及びその製造法 |
| US5395923A (en) | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
| US5707643A (en) | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| US5800373A (en) | 1995-03-23 | 1998-09-01 | Focal, Inc. | Initiator priming for improved adherence of gels to substrates |
| DE69414558T2 (de) | 1993-03-23 | 1999-07-15 | Focal, Inc., Lexington, Mass. | Gerät und methode für den lokalen auftrag von polymermaterial auf gewebe |
| ES2119201T3 (es) | 1993-04-28 | 1998-10-01 | Focal Inc | Aparato, producto y uso relacionados con la fototermoconformacion intraluminal. |
| US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| US5409703A (en) | 1993-06-24 | 1995-04-25 | Carrington Laboratories, Inc. | Dried hydrogel from hydrophilic-hygroscopic polymer |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5431639A (en) | 1993-08-12 | 1995-07-11 | Boston Scientific Corporation | Treating wounds caused by medical procedures |
| WO1995005161A1 (en) | 1993-08-13 | 1995-02-23 | Vitaphore Corporation | Hydrogel-based microsphere drug delivery systems |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5589194A (en) | 1993-09-20 | 1996-12-31 | Minnesota Mining And Manufacturing Company | Method of encapsulation and microcapsules produced thereby |
| US5578638A (en) | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5650173A (en) | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| DE4341113B4 (de) | 1993-12-02 | 2006-04-13 | IFAC Institut für angewandte Colloidtechnologie GmbH & Co. KG | Stabile multiple X/O/Y-Emulsion |
| EP0731693A1 (en) | 1993-12-08 | 1996-09-18 | Vitaphore Corporation | Microsphere drug delivery system |
| US5423821A (en) | 1994-01-18 | 1995-06-13 | Pasque; Michael K. | Sternal closure device |
| US5385561A (en) | 1994-01-18 | 1995-01-31 | Bard International, Inc. | Apparatus and method for injecting a viscous material into the tissue of a patient |
| CA2140053C (en) | 1994-02-09 | 2000-04-04 | Joel S. Rosenblatt | Collagen-based injectable drug delivery system and its use |
| US5717614A (en) | 1994-05-04 | 1998-02-10 | National Instruments Corporation | System and method for handling events in an instrumentation system |
| US5480914A (en) | 1994-05-06 | 1996-01-02 | Allergan, Inc. | Nonaqueous thixotropic drug delivery suspensions and methods of their use |
| EP0712635B1 (en) | 1994-05-13 | 2003-05-02 | Kuraray Co., Ltd. | Medical polymer gel |
| KR0141431B1 (ko) | 1994-05-17 | 1998-07-01 | 김상웅 | 생분해성 하이드로겔 고분자 |
| US5419491A (en) | 1994-05-23 | 1995-05-30 | Mattson Spray Equipment, Inc. | Two component fluid spray gun and method |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| US5665063A (en) | 1994-06-24 | 1997-09-09 | Focal, Inc. | Methods for application of intraluminal photopolymerized gels |
| US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
| US5509899A (en) | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
| US5665840A (en) | 1994-11-18 | 1997-09-09 | Novartis Corporation | Polymeric networks from water-soluble prepolymers |
| EP0713707A1 (en) | 1994-11-23 | 1996-05-29 | Collagen Corporation | In situ crosslinkable, injectable collagen composition for tissue augmention |
| US5588960A (en) | 1994-12-01 | 1996-12-31 | Vidamed, Inc. | Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5849412A (en) | 1995-02-17 | 1998-12-15 | Medlogic Global Corporation | Encapsulated materials |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| EP0810853B1 (en) | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
| US5962023A (en) | 1995-03-06 | 1999-10-05 | Ethicon, Inc. | Hydrogels containing absorbable polyoxaamides |
| US5618850A (en) | 1995-03-09 | 1997-04-08 | Focal, Inc. | Hydroxy-acid cosmetics |
| US6962979B1 (en) | 1995-03-14 | 2005-11-08 | Cohesion Technologies, Inc. | Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents |
| CA2165728A1 (en) | 1995-03-14 | 1996-09-15 | Woonza M. Rhee | Use of hydrophobic crosslinking agents to prepare crosslinked biomaterial compositions |
| DE69637198T2 (de) | 1995-03-23 | 2008-05-08 | Genzyme Corp., Cambridge | Redox und photoinitiatorsystem zur grundierung von verbesserter adhäsion von gelen zu substraten |
| US5900245A (en) | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US6902743B1 (en) | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
| US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
| US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
| US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
| US6201065B1 (en) | 1995-07-28 | 2001-03-13 | Focal, Inc. | Multiblock biodegradable hydrogels for drug delivery and tissue treatment |
| US5769882A (en) | 1995-09-08 | 1998-06-23 | Medtronic, Inc. | Methods and apparatus for conformably sealing prostheses within body lumens |
| WO1997010858A1 (en) | 1995-09-21 | 1997-03-27 | Quinton Instrument Company | Tapered and reinforced catheter |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5741292A (en) | 1995-10-26 | 1998-04-21 | Eagle Vision | Punctum dilating and plug inserting instrument with push-button plug release |
| US6678553B2 (en) | 1995-11-21 | 2004-01-13 | Intraabrain International Nv | Device for enhanced delivery of biologically active substances and compounds in an organism |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| US5824040A (en) | 1995-12-01 | 1998-10-20 | Medtronic, Inc. | Endoluminal prostheses and therapies for highly variable body lumens |
| US5990193A (en) | 1995-12-12 | 1999-11-23 | University Of Pittsburgh | Polymers for reversible photoinduced sol gel transitions |
| EP1704878B1 (en) | 1995-12-18 | 2013-04-10 | AngioDevice International GmbH | Crosslinked polymer compositions and methods for their use |
| US5752974A (en) | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
| US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| US5650450A (en) | 1996-01-25 | 1997-07-22 | Foamex L.P. | Hydrophilic urethane foam |
| US5702361A (en) | 1996-01-31 | 1997-12-30 | Micro Therapeutics, Inc. | Method for embolizing blood vessels |
| US5608938A (en) | 1996-02-08 | 1997-03-11 | Baschenis; Bruno | Bottle brush assembly |
| BR9708046A (pt) | 1996-03-11 | 2000-01-04 | Focal Inc | Método para radioterapia local nim paciente e respectiva composição. |
| DE19612628A1 (de) | 1996-03-29 | 1997-10-02 | Hoechst Ag | Verfahren zur Herstellung von porösen hydrophilen, hochquellfähigen Hydrogelen |
| GB9608222D0 (en) | 1996-04-20 | 1996-06-26 | Innovative Tech Ltd | Dehydrated hydrogels |
| CA2259370C (en) | 1996-07-02 | 2007-10-23 | Minnesota Mining And Manufacturing Company | Medical adhesive composite and package |
| US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
| GB9616672D0 (en) | 1996-08-08 | 1996-09-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| US8003705B2 (en) * | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
| WO1998012274A1 (en) | 1996-09-23 | 1998-03-26 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
| US7009034B2 (en) | 1996-09-23 | 2006-03-07 | Incept, Llc | Biocompatible crosslinked polymers |
| ZA978537B (en) | 1996-09-23 | 1998-05-12 | Focal Inc | Polymerizable biodegradable polymers including carbonate or dioxanone linkages. |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6071875A (en) | 1996-12-04 | 2000-06-06 | Alcon Laboratories, Inc. | TGFα for the treatment of ocular hypertension and glaucoma |
| US5888493A (en) | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| US20070185033A1 (en) | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5718916A (en) | 1997-02-03 | 1998-02-17 | Scherr; George H. | Alginate foam products |
| WO1998035631A1 (en) | 1997-02-14 | 1998-08-20 | Pathak Chandrashekar | Biocompatible polymers and methods for their use |
| US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
| JP2001516261A (ja) | 1997-03-20 | 2001-09-25 | フォーカル・インコーポレーテッド | 生物分解性の組織開創器 |
| US6082362A (en) | 1997-03-27 | 2000-07-04 | Eagle Vision, Inc. | Punctum plug |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| US5906997A (en) | 1997-06-17 | 1999-05-25 | Fzio Med, Inc. | Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions |
| US6153211A (en) | 1997-07-18 | 2000-11-28 | Infimed, Inc. | Biodegradable macromers for the controlled release of biologically active substances |
| US6162241A (en) | 1997-08-06 | 2000-12-19 | Focal, Inc. | Hemostatic tissue sealants |
| US5830171A (en) | 1997-08-12 | 1998-11-03 | Odyssey Medical, Inc. | Punctal occluder |
| US6150505A (en) | 1997-09-19 | 2000-11-21 | Hadasit Medical Research Services & Development Ltd. | Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII |
| WO1999021512A1 (en) | 1997-10-27 | 1999-05-06 | The Regents Of The University Of California | Methods and pharmaceutical compositions for the closure of retinal breaks |
| US6645963B2 (en) | 1997-11-05 | 2003-11-11 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
| JP2001507722A (ja) | 1997-11-06 | 2001-06-12 | オーボン コーポレイション | 薬物送達のための安定化乾燥薬学的組成物、およびそれを調製する方法 |
| KR20010015856A (ko) | 1997-12-12 | 2001-02-26 | 마크로메드 인코퍼레이션 | 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜) |
| FR2773320B1 (fr) | 1998-01-05 | 2000-03-03 | Optisinvest | Dispositif pour le transfert intraoculaire de produits actifs par iontophorese |
| ES2211033T3 (es) | 1998-01-07 | 2004-07-01 | Debio Recherche Pharmaceutique S.A. | Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos. |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| SE9800853D0 (sv) | 1998-03-16 | 1998-03-16 | Pharmacia & Upjohn Bv | Intraocular lens |
| US6007833A (en) | 1998-03-19 | 1999-12-28 | Surmodics, Inc. | Crosslinkable macromers bearing initiator groups |
| US6251382B1 (en) | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6196993B1 (en) | 1998-04-20 | 2001-03-06 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
| US6156531A (en) | 1998-07-20 | 2000-12-05 | Sulzer Carbomedics Inc. | Cross-linking tissue with a compound having a C8 to C40 aliphatic chain |
| US6206930B1 (en) | 1998-08-10 | 2001-03-27 | Charlotte-Mecklenburg Hospital Authority | Absorbable tissue expander |
| US7347850B2 (en) * | 1998-08-14 | 2008-03-25 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
| US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
| US6703047B2 (en) | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
| US6605294B2 (en) | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
| US7790192B2 (en) | 1998-08-14 | 2010-09-07 | Accessclosure, Inc. | Apparatus and methods for sealing a vascular puncture |
| US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| AU5560899A (en) | 1998-08-14 | 2000-03-06 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
| US6179862B1 (en) | 1998-08-14 | 2001-01-30 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
| US6152943A (en) | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
| US6514534B1 (en) | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
| US6458147B1 (en) | 1998-11-06 | 2002-10-01 | Neomend, Inc. | Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue |
| AU759016B2 (en) | 1998-10-05 | 2003-04-03 | Penn State Research Foundation, The | Compositions and methods for enhancing receptor-mediated cellular internalization |
| US6899889B1 (en) | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
| US6110484A (en) | 1998-11-24 | 2000-08-29 | Cohesion Technologies, Inc. | Collagen-polymer matrices with differential biodegradability |
| AU2707500A (en) * | 1998-12-04 | 2000-06-26 | Incept Llc | Biocompatible crosslinked polymers |
| US20080114092A1 (en) | 1998-12-04 | 2008-05-15 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
| DE19857111A1 (de) * | 1998-12-11 | 2000-06-15 | Dyneon Gmbh | Wäßrige Dispersionen von Fluorpolymeren |
| WO2004073708A1 (en) | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
| US6528107B2 (en) | 1999-01-19 | 2003-03-04 | Sulzer Carbomedics Inc. | Method for producing antimicrobial antithrombogenic medical devices |
| US6958212B1 (en) | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
| US6410045B1 (en) | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6217896B1 (en) | 1999-04-01 | 2001-04-17 | Uab Research Foundation | Conjunctival inserts for topical delivery of medication or lubrication |
| US6322593B1 (en) | 1999-04-09 | 2001-11-27 | Sulzer Carbomedics Inc. | Method for treating cross-linked biological tissues |
| US6177514B1 (en) | 1999-04-09 | 2001-01-23 | Sulzer Carbomedics Inc. | Blocked functional reagants for cross-linking biological tissues |
| DK1168934T3 (da) | 1999-04-12 | 2008-05-13 | Cornell Res Foundation Inc | Hydrogeldannende system med hydrofobe og hydrofile komponenter |
| US6716445B2 (en) | 1999-04-12 | 2004-04-06 | Cornell Research Foundation, Inc. | Hydrogel entrapping therapeutic agent and stent with coating comprising this |
| US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
| US6132986A (en) | 1999-04-23 | 2000-10-17 | Sulzer Carbomedics Inc. | Tissue crosslinking for bioprostheses using activated difunctional or polyfunctional acids |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| US6539251B2 (en) | 1999-05-25 | 2003-03-25 | Iomed, Inc. | Ocular iontophoretic apparatus |
| US6319240B1 (en) | 1999-05-25 | 2001-11-20 | Iomed, Inc. | Methods and apparatus for ocular iontophoresis |
| WO2001016210A1 (en) | 1999-08-27 | 2001-03-08 | Cohesion Technologies, Inc. | Compositions that form interpenetrating polymer networks for use as high strength medical sealants |
| US6409757B1 (en) | 1999-09-15 | 2002-06-25 | Eva Corporation | Method and apparatus for supporting a graft assembly |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6710126B1 (en) | 1999-11-15 | 2004-03-23 | Bio Cure, Inc. | Degradable poly(vinyl alcohol) hydrogels |
| US6220246B1 (en) | 1999-11-23 | 2001-04-24 | Becton Dickinson And Company | Ophthalmic surgical sponge for protection of a corneal cap |
| US6479079B1 (en) | 1999-12-13 | 2002-11-12 | Sulzer Carbomedics Inc. | Anticalcification treatments for fixed biomaterials |
| ES2391763T3 (es) | 2000-04-07 | 2012-11-29 | Collagen Matrix, Inc. | Dispositivo de embolización |
| US20050277864A1 (en) | 2000-04-14 | 2005-12-15 | David Haffner | Injectable gel implant for glaucoma treatment |
| US20040175410A1 (en) * | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6679605B2 (en) | 2000-05-22 | 2004-01-20 | Medennium, Inc. | Crystalline polymeric compositions for ophthalmic devices |
| US6692759B1 (en) | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| EP1301210A2 (en) | 2000-07-14 | 2003-04-16 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
| AU2001286651A1 (en) | 2000-08-22 | 2002-03-04 | Purdue Research Foundation | Microparticle composition and method |
| AU2001271417B2 (en) | 2000-08-30 | 2006-10-05 | Johns Hopkins University | Devices for intraocular drug delivery |
| US6303102B1 (en) | 2000-09-07 | 2001-10-16 | Kenneth Schlichte | Cutaneously applied biodegradable tell-tale having controllable clearing time |
| US6579519B2 (en) | 2000-09-18 | 2003-06-17 | Registrar, University Of Delhi | Sustained release and long residing ophthalmic formulation and the process of preparing the same |
| US6610033B1 (en) | 2000-10-13 | 2003-08-26 | Incept, Llc | Dual component medicinal polymer delivery system and methods of use |
| US7060297B2 (en) | 2000-11-06 | 2006-06-13 | Alcon, Inc. | Carrageenan viscoelastics for ocular surgery |
| US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US6703039B2 (en) | 2000-12-06 | 2004-03-09 | Bausch & Lomb Incorporated | Reversible gelling system for ocular drug delivery |
| US6596471B2 (en) | 2000-12-21 | 2003-07-22 | Carbomedics Inc. | Method of cross-linking tissue with a bis-maleimide compound |
| CA2438193A1 (en) | 2001-02-26 | 2002-09-06 | Duke University | Novel dendritic polymers and their biomedical uses |
| US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
| US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US6747090B2 (en) | 2001-07-16 | 2004-06-08 | Pharmacia Groningen Bv | Compositions capable of forming hydrogels in the eye |
| US20030185892A1 (en) | 2001-08-17 | 2003-10-02 | Bell Steve J. D. | Intraocular delivery compositions and methods |
| US7204995B2 (en) * | 2002-01-31 | 2007-04-17 | El-Sherif Dalia M | Treatment and control of dry eye by use of biodegradable polymer capsules |
| DK1484054T3 (da) | 2002-02-22 | 2012-11-26 | Santen Pharmaceutical Co Ltd | Lægemiddelafgivelsessystem til subkonjunktival indgivelse af fine korn |
| US20040131582A1 (en) | 2002-02-26 | 2004-07-08 | Grinstaff Mark W. | Novel dendritic polymers and their biomedical uses |
| WO2003074076A2 (en) | 2002-02-28 | 2003-09-12 | The Penn State Research Foundation | Periocular drug delivery for diabetic retinopathy |
| EP1364663A1 (en) | 2002-05-21 | 2003-11-26 | Commonwealth Scientific And Industrial Research Organisation | Ocular devices with functionalized surface with adhesive properties |
| AU2003279730A1 (en) | 2002-09-30 | 2004-04-19 | Fibrogen, Inc. | Dry tissue sealant compositions |
| US20040147016A1 (en) | 2002-09-30 | 2004-07-29 | Rowley Jonathan A. | Programmable scaffold and methods for making and using the same |
| US20040063206A1 (en) | 2002-09-30 | 2004-04-01 | Rowley Jon A. | Programmable scaffold and method for making and using the same |
| JP4584713B2 (ja) | 2002-10-08 | 2010-11-24 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物 |
| US20050043220A1 (en) | 2002-11-08 | 2005-02-24 | Guyer David R. | Methods and compositions for treating macular degeneration |
| JP2004196787A (ja) | 2002-12-04 | 2004-07-15 | Santen Pharmaceut Co Ltd | 結膜下デポによるドラッグデリバリーシステム |
| EP1568359A4 (en) | 2002-12-04 | 2011-05-18 | Santen Pharmaceutical Co Ltd | DRUG DELIVERY SYSTEM HAVING SUB-CONJUNCTIVAL DEPOSIT |
| NZ540885A (en) * | 2002-12-20 | 2009-02-28 | Chakshu Res Inc | Ophthalmic formulation for the prevention and treatment of ocular conditions |
| US6863924B2 (en) | 2002-12-23 | 2005-03-08 | Kimberly-Clark Worldwide, Inc. | Method of making an absorbent composite |
| WO2004073551A2 (en) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
| US8545830B2 (en) | 2003-03-24 | 2013-10-01 | University Of Tennessee Research Foundation | Multi-functional polymeric materials and their uses |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US7273896B2 (en) | 2003-04-10 | 2007-09-25 | Angiotech Pharmaceuticals (Us), Inc. | Compositions and methods of using a transient colorant |
| US7017580B2 (en) | 2003-05-22 | 2006-03-28 | Clarity Corporation | Punctum plug system including a punctum plug and passive insertion tool therefor |
| US7129210B2 (en) | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
| KR101160702B1 (ko) | 2003-08-20 | 2012-06-28 | 산텐 세이야꾸 가부시키가이샤 | 미립자 테논낭하 투여 약물 전달 시스템 |
| US20090240276A1 (en) | 2003-11-04 | 2009-09-24 | Parviz Robert Ainpour | Gel Plug For Blockage Of The Canaliculus |
| US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
| FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
| US20050197614A1 (en) * | 2004-03-04 | 2005-09-08 | Wilson Pritchard | Occlusive biomedical devices, punctum plugs, and methods of use thereof |
| US20050220882A1 (en) | 2004-03-04 | 2005-10-06 | Wilson Pritchard | Materials for medical implants and occlusive devices |
| US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| WO2005120462A2 (en) | 2004-06-07 | 2005-12-22 | Callisyn Pharmaceuticals, Inc. | Biodegradable and biocompatible crosslinked polymer hydrogel prepared from pva and/or peg macromer mixtures |
| WO2006002366A2 (en) | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable ocular devices, methods and systems |
| WO2006002365A2 (en) * | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
| EP1768692B8 (en) | 2004-07-01 | 2015-06-17 | Yale University | Targeted and high density drug loaded polymeric materials |
| DE602004022523D1 (de) | 2004-07-02 | 2009-09-24 | Novagali Pharma Sa | Verwendung von Emulsionen zur intra- und periocularen Injection |
| CN101052435B (zh) | 2004-07-02 | 2010-12-08 | Qlt塞子传递公司 | 治疗介质递送装置 |
| FR2872975A1 (fr) | 2004-07-06 | 2006-01-13 | Thomson Licensing Sa | Procede et dispositif pour choisir un mode de codage |
| WO2006031358A2 (en) | 2004-08-13 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses |
| WO2006031388A2 (en) | 2004-08-20 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dentritic polymers, crosslinked gels, and their uses in orthopedic applications |
| EP1796693A2 (en) | 2004-08-26 | 2007-06-20 | Chandrashekhar P. Pathak | Implantable tissue compositions and method |
| US20080038317A1 (en) * | 2004-09-10 | 2008-02-14 | Chin-Ming Chang | Therapeutic Lacrimal Canalicular Inserts And Related Methods |
| US7495052B2 (en) | 2004-09-15 | 2009-02-24 | Bausch & Lomb Incorporated | Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility |
| US20060074370A1 (en) | 2004-09-24 | 2006-04-06 | Medennium, Inc. | Ocular occluder and method of insertion |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US7857849B2 (en) | 2004-10-05 | 2010-12-28 | The Board Of Trustees Of The Leland Stanford Junior Iniversity | Artificial corneal implant |
| US8790632B2 (en) | 2004-10-07 | 2014-07-29 | Actamax Surgical Materials, Llc | Polymer-based tissue-adhesive form medical use |
| US20080132444A1 (en) | 2004-10-09 | 2008-06-05 | Xiaoling Li | Ocular Agent Delivery Systems |
| ATE412400T1 (de) | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
| JP2008520783A (ja) * | 2004-11-16 | 2008-06-19 | ユニベルシテ・ド・リエージュ | ヒドロゲルマトリックスおよびマイクロキャリアを含む活性物質供給システム |
| GB2438544A (en) | 2005-02-09 | 2007-11-28 | Cooper Internat Corp | Liquid formulations for treatment of diseases or conditions |
| US20060233858A1 (en) | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
| US7825087B2 (en) | 2005-04-12 | 2010-11-02 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
| WO2007001926A2 (en) | 2005-06-24 | 2007-01-04 | Hyperbranch Medical Technology, Inc. | Low-swelling hydrogel sealants for wound repair |
| WO2007005249A2 (en) | 2005-06-29 | 2007-01-11 | Hyperbranch Medical Technology, Inc. | Nanoparticles and dendritic-polymer-based hydrogels comprising them |
| WO2007009061A2 (en) | 2005-07-13 | 2007-01-18 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
| FR2890861B1 (fr) | 2005-09-16 | 2010-05-28 | Galderma Res & Dev | Compositions comprenant au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethanes ou des derives de celui-ci, leurs procede de preparation, et leur utilisation |
| CA2636716C (en) | 2006-01-13 | 2014-12-23 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
| EP1988936B1 (en) | 2006-02-17 | 2014-08-06 | Novartis AG | Ophtalmic product and method for sterilization |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8795709B2 (en) | 2006-03-29 | 2014-08-05 | Incept Llc | Superabsorbent, freeze dried hydrogels for medical applications |
| ES2640458T3 (es) | 2006-03-31 | 2017-11-03 | Mati Therapeutics Inc. | Implantes del sistema de drenaje nasolagrimal para terapia medicamentosa |
| JP6075930B2 (ja) | 2006-04-24 | 2017-02-08 | インセプト エルエルシー | タンパク質架橋剤、架橋方法及びその用途 |
| US7872068B2 (en) | 2006-05-30 | 2011-01-18 | Incept Llc | Materials formable in situ within a medical device |
| US20080045911A1 (en) * | 2006-06-21 | 2008-02-21 | Borgia Maureen J | Punctal plugs for the delivery of active agents |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| BRPI0718543A2 (pt) | 2006-11-06 | 2013-11-12 | Novartis Ag | Dispositivos oculares e métodos de fabricação e uso dos mesmos |
| US20080214223A1 (en) | 2007-01-23 | 2008-09-04 | Source Of Sound Ltd. | Push-to-talk pressing device |
| US20090227981A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
| US20080220047A1 (en) | 2007-03-05 | 2008-09-11 | Sawhney Amarpreet S | Low-swelling biocompatible hydrogels |
| US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| WO2009012406A1 (en) * | 2007-07-17 | 2009-01-22 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities reference to priority document |
| KR20100058620A (ko) | 2007-09-07 | 2010-06-03 | 큐엘티 플러그 딜리버리, 인코포레이티드 | 눈물 임플랜트용 삽입 및 적출 기구 |
| CA2698508C (en) | 2007-09-07 | 2017-06-06 | Alan R. Rapacki | Lacrimal implants and related methods |
| EP2247645B1 (en) | 2008-02-13 | 2017-12-06 | Hyperbranch Medical Technology, Inc. | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates |
| RU2010136822A (ru) | 2008-02-18 | 2012-03-10 | Клт Плаг Диливери, Инк. (Us) | Лакримальные имплантаты и связанные с ними способы |
| EP2276420B1 (en) | 2008-04-04 | 2021-10-06 | Journey1, Inc. | Device to treat an eye having an epithelium with a defect |
| US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US20100158980A1 (en) | 2008-12-18 | 2010-06-24 | Casey Kopczynski | Drug delivery devices for delivery of therapeutic agents |
| US8430853B2 (en) | 2010-02-05 | 2013-04-30 | Johnson & Johnson Vision Care, Inc. | Implantation instruments, system, and kit for punctal implants |
-
2010
- 2010-02-12 EP EP10741771.9A patent/EP2396070B1/en active Active
- 2010-02-12 JP JP2011550256A patent/JP5890182B2/ja active Active
- 2010-02-12 CA CA2750242A patent/CA2750242C/en active Active
- 2010-02-12 CN CN201080016295.1A patent/CN102395401B/zh active Active
- 2010-02-12 WO PCT/US2010/024029 patent/WO2010093873A2/en not_active Ceased
- 2010-02-12 US US12/704,692 patent/US8409606B2/en active Active
- 2010-02-12 AU AU2010213612A patent/AU2010213612B2/en active Active
-
2013
- 2013-02-26 US US13/777,103 patent/US8563027B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2750242A1 (en) | 2010-08-19 |
| AU2010213612A1 (en) | 2011-08-25 |
| US8409606B2 (en) | 2013-04-02 |
| EP2396070A4 (en) | 2012-09-19 |
| CN102395401B (zh) | 2015-08-19 |
| WO2010093873A3 (en) | 2011-04-14 |
| CN102395401A (zh) | 2012-03-28 |
| US20130172268A1 (en) | 2013-07-04 |
| EP2396070B1 (en) | 2024-12-04 |
| JP2012517330A (ja) | 2012-08-02 |
| US8563027B2 (en) | 2013-10-22 |
| EP2396070A2 (en) | 2011-12-21 |
| EP2396070C0 (en) | 2024-12-04 |
| US20100209478A1 (en) | 2010-08-19 |
| AU2010213612B2 (en) | 2015-04-30 |
| JP5890182B2 (ja) | 2016-03-22 |
| WO2010093873A2 (en) | 2010-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2750242C (en) | Drug delivery through hydrogel plugs | |
| JP7256226B2 (ja) | ハイドロゲルからの薬物送達 | |
| US20250144012A1 (en) | Intracameral drug delivery depots | |
| CA3006303C (en) | Shape changing drug delivery devices and methods | |
| JP7092502B2 (ja) | ハイドロゲル薬物送達インプラント | |
| US8961501B2 (en) | Method for applying flowable hydrogels to a cornea | |
| JP6199883B2 (ja) | 医療用オルガノゲルプロセス及び組成物 | |
| BR122024018825A2 (pt) | Composição de depósito e uso da mesma para tratamento de uma condição ocular | |
| BR112019005594B1 (pt) | Composição de depósito intracameral e uso da mesma para tratamento de uma condição ocular | |
| HK1261346A1 (en) | Shape changing drug delivery devices and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150114 |